Emerging drugs for adrenocortical carcinoma

被引：30

作者：

Berruti, Alfredo ^{[1
]}

Ferrero, Anna ^{[1
]}

Sperone, Paola ^{[1
]}

Daffara, Fulvia ^{[2
]}

Reimondo, Giuseppe ^{[2
]}

Papotti, Mauro ^{[2
]}

Dogliotti, Luigi ^{[1
]}

Angeli, Alberto ^{[2
]}

Terzolo, Massimo ^{[2
]}

机构：

[1] Univ Turin, Dept Clin & Biol Sci, Azienda Osped San Luigi, I-10043 Orbassano, Italy

[2] Azienda Osped San Luigi Gonzaga, Orbassano, Italy

来源：

EXPERT OPINION ON EMERGING DRUGS | 2008年 / 13卷 / 03期

关键词：

adrenocortical carcinoma; chemotherapy; mitotane; target therapies;

D O I：

10.1517/14728214.13.3.497

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Adrenocortical carcinoma (ACC) is an extremely rare aggressive disease. Few data are available on the efficacy of systemic antineoplastic treatments (mitotane and cytotoxic therapy) in the treatment of advanced disease. Objective/methods: this paper will review the existing treatment strategies and new perspectives in the management of ACC patients. Results/conclusion: An ongoing randomized international trial aims to define the best combination chemotherapy plus mitotane regimen. Based on the results of a case control study, mitotane is being explored as adjuvant therapy. Genetic and biological studies have identified molecular targets for specific targeted drugs such as IGF receptor inhibitors and antiangiogenetic drugs. Phase II trials are exploring the activity of these drugs either alone or in combination with chemotherapy.

引用

页码：497 / 509

页数：13

共 98 条

[1] Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients [J].

Abiven, Gwenaelle ;

Coste, Joel ;

Groussin, Lionel ;

Anract, Philippe ;

Tissier, Frederique ;

Legmann, Paul ;

Dousset, Bertrand ;

Bertagna, Xavier ;

Bertherat, Jerome .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (07) :2650-2655

[2] A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma - Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a p-glycoprotein antagonist [J].

Abraham, J ;

Bakke, S ;

Rutt, A ;

Meadows, B ;

Merino, M ;

Alexander, R ;

Schrump, D ;

Bartlett, D ;

Choyke, P ;

Robey, R ;

Hung, E ;

Steinberg, SM ;

Bates, S ;

Fojo, T .

CANCER, 2002, 94 (09) :2333-2343

[3]

ADVANI A, J CLIN PATH IN PRESS

[4] Cytotoxic treatment of adrenocortical carcinoma [J].

Ahlman, H ;

Khorram-Manesh, A ;

Jansson, S ;

Wängberg, B ;

Nilsson, O ;

Jacobsson, CE ;

Lindstedt, S .

WORLD JOURNAL OF SURGERY, 2001, 25 (07) :927-933

[5] Management of adrenocortical carcinoma [J].

Allolio, B ;

Hahner, S ;

Weismann, D ;

Fassnacht, M .

CLINICAL ENDOCRINOLOGY, 2004, 60 (03) :273-287

[6]

ALLOLIO B, 2008, INT ADR CANC S ANN A

[7]

Allolio B, 2006, J CLIN ENDOCR METAB, V60, P273

[8] The molecular pathogenesis of childhood adrenocortical tumors [J].

Almeida, M. Q. ;

Latronico, A. C. .

HORMONE AND METABOLIC RESEARCH, 2007, 39 (06) :461-466

[9] The molecular genetics of adrenocortical carcinoma [J].

Barlaskar, Ferdous M. ;

Hammer, Gary D. .

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2007, 8 (04) :343-348

[10]

Barzon L, 1997, ONCOLOGY, V54, P490

← 1 2 3 4 5 6 7 8 9 10 →